BioNTech SE (BNTX)
|Net Income (ttm)||-201.19M|
|Trading Day||January 20|
|Day's Range||102.33 - 105.50|
|52-Week Range||28.55 - 129.54|
Covid-19 pharma stocks like NVAX stock and BNTX stock are making headlines as Joe Biden promises to vaccinate 100 million Americans. The post Covid-19 Vaccine Roundup: 5 Pharma Stocks Making t...
The coronavirus vaccine developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX) works against a new strain of coronavirus that appeared in the U.K., according to a preprint m...
Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture
New York and Mainz, Germany, January 20, 2021 — Today, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an in vitro study that provides additional data on the capa...
The Covid vaccine developed by Pfizer-BioNTech is likely to be effective against a mutant strain of the virus that was first discovered in the U.K.
New York Governor Andrew Cuomo asked Pfizer Inc (NYSE: PFE) to sell its COVID-19 vaccine directly to New York in a letter on Monday. What Happened: The governor wrote to the New York-based pha...
Biden's Covid Advisory Board member Dr. Celine Gounder said that Cuomo's request to buy the Pfizer vaccine directly, could cause more problems than it solves.
Cuomo asked Pfizer to sell its COVID-19 vaccine directly to New York, just as the head of the WHO warns of mounting inequities in vaccine distribution
New York Gov. Andrew Cuomo called on pharmaceutical company Pfizer to sell doses of its coronavirus vaccine directly to New York state, in the hopes of accelerating a process that has languish...
The request comes after an alarmingly slow start to the national vaccine rollout, with the country millions of injections short of initial projections.
Pfizer will temporarily reduce the number of doses of its coronavirus vaccine being delivered to Europe, according to the Norwegian Institute of Public Health.
Just because they did it in 2020 doesn't mean they won't outrun the market again in the new year.
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
The companies also expect to apply their mRNA vaccine technology to other diseases, such as flu.
COVID-19 Vaccine Production to Ramp Up
"I think the main bottleneck right now is to make sure we ramp up our prioritization so we can administer more vaccines," Pfizer CEO Albert Bourla told CNBC.
Pfizer CEO Albert Bourla on Covid vaccine manufacturing outlook
Pfizer CEO Albert Bourla told CNBC's "Squawk Box" Tuesday that the company plans to increase coronavirus vaccine production this year, with a goal of manufacturing up to two billion doses.
Biden gets second dose of Pfizer vaccine
President-elect Joe Biden got his second shot of the Pfizer Covid-19 vaccine today.
Its CEO is confident that the company's coronavirus vaccine can weather several big challenges it faces.
Public health experts have expressed concern the new mutant strains could pose a threat to inoculation efforts.
Germany's BioNTech SE said Monday it is aiming to supply up to 2 billion doses of its COVID-19 vaccine in 2021, after receiving emergency use authorization in both the U.S. and EU. In a regula...
BioNTech CEO: Pfizer-BioNTech vaccine effective against strains in UK, South Africa
BioNTech CEO Ugur Sahin joined "Squawk Box" on Monday to discuss how effective the Pfizer-BioNTech's coronavirus vaccine is at protecting against the variants of the virus researchers have doc...
Add these top growth stocks to your portfolio before it's too late.
A mutating COVID-19 virus forces the world to cut corners on vaccine strategy. The Herd Immunity strategy has been unofficially suspended for a pressing need strategy.
The European Union is planning to double its supply of Pfizer's coronavirus vaccine by purchasing up to 300 million additional doses, officials said Friday. The deal would add to the EU's exis...
Pfizer's Covid vaccine appears to stop variants found in U.K., South Africa
Pfizer's vaccine appears to neutralize the Covid variants found in the U.K. and South Africa. The study was conducted by Pfizer and has not been peer reviewed.
Coronavirus: Study shows Pfizer-Biontech vaccine may be effective against variant strains
Yahoo Finance's Anjalee Khemlani reports on the latest developments on the coronavirus pandemic, vaccines, and the new variant strains of COVID-19. For 2020 election results please visit: Elec...
BioNTech stock popped Friday after a small test showed its Pfizer-partnered coronavirus vaccine could work against more infectious variants plaguing the U.K. and South Africa. The post BioNTec...
BioNTech jumped as much as 7% on Friday after a study was published showing that its COVID-19 vaccine is effective against a mutated strain of COVID-19 that has been found in the UK in recent ...
Former FDA chief Scott Gottlieb on Pfizer vaccine's ability to neutralize Covid variants
A coronavirus vaccine developed by Pfizer and BioNTech appears to be effective against a key mutation in the more infectious variants of the virus discovered in the U.K. and South Africa, acco...
The European Medicines Agency said Friday that the product information for BioNTech SE and Pfizer Inc.'s COVID-19 vaccine should be updated to say there are six doses in each vial. The authori...
The EU has secured access to up to 300 million extra Pfizer doses, following criticism for its slow COVID-19 vaccine rollout
The EU has secured access to 300 million more doses of Pfizer and BioNTech's COVID-19 vaccine, the president of the European Commission, Ursula von der Leyen, said during a press conference Fr...
The UK's chief medical officers want to delay second doses of the Pfizer/BioNTech vaccine. Is this much ado about nothing for PFE stock?
Pfizer–BioNTech vaccine appears to protect against U.K. and South African COVID-19 strains, study finds
BioNTech said that the company would be able to adjust the vaccine developed with Pfizer to address new mutations of a coronavirus if necessary.
Pfizer-BioNTech Vaccine Appears Resistant To New Covid Variant, Study Finds, As U.S. Records Deadliest Day
The American pharma giant tested its mRNA Covid-19 vaccine against the coronavirus mutants spreading rapidly through the U.K. and South Africa.
Pfizer and BioNTech say COVID-19 vaccine neutralizes mutation found in new U.K., South Africa variants
Pfizer Inc. and German partner BioNTech SE said Friday an in vitro study found that their COVID-19 vaccine neutralizes the two new highly infectious variants that have emerged in the U.K. and ...
The research, which has not yet been peer-reviewed, suggested the Pfizer-BioNTech vaccine worked to neutralize the so-called N501Y mutation.
The EU is doubling its purchases of the Pfizer-BioNTech coronavirus vaccine at a time of growing concern over its rollout.
An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission
New York and Mainz, Germany, January 8, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of T...
The study is preliminary and has not yet been reviewed by experts, a key step for medical research.
Pfizer Inc (NYSE: PFE)/BionNTech SE (NASDAQ: BNTX) COVID-19 showed signs of working against a mutation found in two highly-contagious COVID-19 virus variants detected in the U.K. and South Afr...
The COVID-19 vaccine from pharmaceutical companies Pfizer and BioNTech looks to be effective against 16 different mutations of the coronavirus, according to a study that has not yet undergone ...
Preliminary data shows Pfizer's mRNA vaccine can effectively neutralize coronavirus variants in lab tests.
MAINZ, GERMANY, January 7, 2021 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the publication of preclinical data on its novel mRNA vaccine approac...
Messenger RNA or mRNA technology has come of age, with the first two Covid-19 vaccines (Moderna and BioNTech/Pfizer) approved by Western regulators being based on the technology. The technolog...
With the U.K. entering a third nationwide lockdown and the COVID-19 pandemic raging through the rest of Europe, vaccines approved for emergency use are in high demand. What Happened: The Euro...
MAINZ, GERMANY, January 5, 2021 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Ugur Sahin, M.D., will present a corporate ov...
FDA Warns Against Tinkering With Pfizer, Moderna Vaccine Regimens After White House Advisor's Comments
The United States Food and Drug Administration has warned against changing the dosing regimen, interval, or mixing of COVID-19 vaccines in a statement issued Monday. What Happened: The health ...
The European Commission could buy even more doses of the biotech's COVID-19 vaccine.
To tap the market's rally, it will be prudent to invest in momentum stocks that are still cheap. Our choices are Winnebago Industries (WGO), Fiat Chrysler (FCAU), FedEx (FDX), Williams-Sonoma ...
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ:ICLR), a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical de...
A lot of money could ride on a planned second version of Pfizer's coronavirus vaccine.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical tr... [Read more...]
|IPO Date |
Oct 10, 2019
Prof. Ugur Sahin M.D.
|Stock Exchange |
|Ticker Symbol |
In 2019, BioNTech SE's revenue was 108.59 million, a decrease of -14.88% compared to the previous year's 127.58 million. Losses were -179.06 million, 272.9% more than in 2018.
According to 10 analysts, the average rating for BioNTech SE stock is "Buy." The 12-month stock price forecast is 117.36, which is an increase of 12.68% from the latest price.